Freda W. Qi

Mount Sinai Hospital
Toronto, ON M5G1X5, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 21 publications

SARS-CoV-2 Infection and COVID-19 Vaccine Antibody Responses in Two Canadian Cohorts of Persons Living with HIV.

SARS-CoV-2 Infection and COVID-19 Vaccine Antibody Responses in Two Canadian Cohorts of Persons Living with HIV.

Journal: Antibodies (Basel, Switzerland)

Published: February 26, 2026

Preserved SARS-CoV-2 T-cell responses despite impaired humoral immunity in children with profound B-cell lymphopenia.

Preserved SARS-CoV-2 T-cell responses despite impaired humoral immunity in children with profound B-cell lymphopenia.

Journal: NPJ vaccines

Published: February 12, 2026

Serological Benefit of SARS-CoV-2 Vaccination Relative to Infection in Children With Acute Lymphoblastic Leukemia.

Serological Benefit of SARS-CoV-2 Vaccination Relative to Infection in Children With Acute Lymphoblastic Leukemia.

Journal: Pediatric blood & cancer

Published: February 10, 2026

Neutralising antibody responses to emerging SARS-CoV-2 omicron sub-variants are enhanced in persons with hybrid immunity.

Neutralising antibody responses to emerging SARS-CoV-2 omicron sub-variants are enhanced in persons with hybrid immunity.

Journal: Clinical & translational immunology

Published: November 11, 2025

SARS-CoV-2 infection in female sex workers from Nairobi, Kenya early in the COVID-19 pandemic: Seroincidence and behavioural associations.

SARS-CoV-2 infection in female sex workers from Nairobi, Kenya early in the COVID-19 pandemic: Seroincidence and behavioural associations.

Journal: PloS one

Published: July 10, 2025

Risk factors for infection with SARS-CoV-2 in a cohort of Canadian healthcare workers: 2020-2023.

Risk factors for infection with SARS-CoV-2 in a cohort of Canadian healthcare workers: 2020-2023.

Journal: Epidemiology and infection

Published: June 23, 2025

Longitudinal Innate and Heterologous Adaptive Immune Responses to SARS-CoV-2 JN.1 in Transplant Recipients With Prior Omicron Infection: Limited Neutralization but Robust CD4+ T-Cell Activity.

Longitudinal Innate and Heterologous Adaptive Immune Responses to SARS-CoV-2 JN.1 in Transplant Recipients With Prior Omicron Infection: Limited Neutralization but Robust CD4+ T-Cell Activity.

Journal: Transplant infectious disease : an official journal of the Transplantation Society

Published: April 17, 2025

Reduced vaccine-induced germinal center outputs in patients with inflammatory bowel disease treated with anti-TNF biologics.

Reduced vaccine-induced germinal center outputs in patients with inflammatory bowel disease treated with anti-TNF biologics.

Journal: The Journal of clinical investigation

Published: March 19, 2025

mRNA vaccine-induced SARS-CoV-2 spike-specific IFN-γ and IL-2 T-cell responses are predictive of serological neutralization and are transiently enhanced by pre-existing cross-reactive immunity.

mRNA vaccine-induced SARS-CoV-2 spike-specific IFN-γ and IL-2 T-cell responses are predictive of serological neutralization and are transiently enhanced by pre-existing cross-reactive immunity.

Journal: Journal of virology

Published: January 31, 2025

Comparison of six COVID-19 serology assays for detection of antibodies from patients infected with ancestral and a spectrum of SARS-CoV-2 variants.

Comparison of six COVID-19 serology assays for detection of antibodies from patients infected with ancestral and a spectrum of SARS-CoV-2 variants.

Journal: Access microbiology

Published: December 24, 2024

Declining Levels of Neutralizing Antibodies to SARS-CoV-2 Omicron Variants Are Enhanced by Hybrid Immunity and Original/Omicron Bivalent Vaccination.

Declining Levels of Neutralizing Antibodies to SARS-CoV-2 Omicron Variants Are Enhanced by Hybrid Immunity and Original/Omicron Bivalent Vaccination.

Journal: Vaccines

Published: April 09, 2024

A bivalent COVID-19 mRNA vaccine elicited broad immune responses and protection against Omicron subvariants infection.

A bivalent COVID-19 mRNA vaccine elicited broad immune responses and protection against Omicron subvariants infection.

Journal: NPJ vaccines

Published: April 04, 2024

Showing 1-12 of 21

Last Updated: 09/26/2026